Top

Published in:

01-09-2014 | Pediatrics (S Gidding, Section Editor)

Treatment of Pediatric Hypertension: Lessons Learned from Recent Clinical Trials

Authors: Michael A. Ferguson, Joseph T. Flynn

Published in: Current Cardiovascular Risk Reports | Issue 9/2014

Abstract

Historically, drugs prescribed for children have not been studied rigorously to assess their efficacy and safety, or appropriateness of dosing regimens. The passage of the Federal Drug Administration Modernization Act in 1997 heralded an era of increased rigor with respect to pediatric drug development by providing financial incentives to industry sponsors for conducting pharmaceutical trials in children. Subsequent legislative efforts have facilitated ongoing attention to this area. Antihypertensive drugs represent one of the largest groups of medications impacted by these efforts. Consequently, a growing number of antihypertensive medications from different classes have been studied in children and adolescents, resulting in more of these agents receiving FDA-approved labeling for use in children and adolescents.

Flynn JT. Pediatric use of antihypertensive medications: much more to learn. Curr Ther Res. 2001;62(4):314–28.CrossRef

Shirkey H, editor. Conference of Professional and Scientific Societies, 27–28 June 1963; Chicago, IL.

US Food and Drug Administration. Food and Drug Administration Modernization Act of 1997. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/default.htm. Accessed 8 Jul 2014.

Pediatric Research Equity Act of 2003. http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm077853.pdf. Accessed 8 Jul 2014.

Best Pharmaceuticals for Children Act. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ucm148011.htm. Accessed 8 Jul 2014.

Public Law 0112-144, The Food and Drug Administration Safety amd Innovation Act. http://www.gpo.gov/fdsys/pkg/PLAW-112publ144/pdf/PLAW-112publ144.pdf. Accessed 8 Jul 2014.

Pasquali SK, Sanders SP, Li JS. Oral antihypertensive trial design and analysis under the pediatric exclusivity provision. Am Heart J. 2002;144(4):608–14.PubMedCrossRef

United States Food and Drug Administration. Written Requests Issued. http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/ucm050002.htm. Accessed 8 Jul 2014.

United States Food and Drug Administration. Drugs to Which FDA has Granted Pediatric Exclusivity for Pediatric Studies under Section 505A of the Federal Food, Drug, and Cosmetic Act. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM223058.pdf. Accessed 8 Jul 2014.

10.

Benjamin Jr DK, Smith PB, Jadhav P, Gobburu JV, Murphy MD, Hasselblad V, et al. Pediatric antihypertensive trial failures: analysis of end points and dose range. Hypertension. 2008;51(4):834–40.

11.

Meyers RS, Siu A. Pharmacotherapy review of chronic pediatric hypertension. Clin Ther. 2011;33(10):1331–56. doi:10.1016/j.clinthera.2011.09.003.PubMedCrossRef

12.

DiBianco R. Angiotensin converting enzyme inhibition. Unique and effective therapy for hypertension and congestive heart failure. Postgrad Med. 1985;78(5):229–41. 244, 247–8.PubMed

13.

Smith CG, Vane JR. The discovery of captopril. FASEB J. 2003;17(8):788–9. doi:10.1096/fj.03-0093life.PubMedCrossRef

14.

Oberfield SE, Case DB, Levine LS, Rapaport R, Rauh W, New MI. Use of the oral angiotensin I-converting enzyme inhibitor (captopril) in childhood malignant hypertension. J Pediatr. 1979;95(4):641–4.PubMedCrossRef

15.

Mirkin BL, Newman TJ. Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group. Pediatrics. 1985;75(6):1091–100.PubMed

16.

Sinaiko AR, Kashtan CE, Mirkin BL. Antihypertensive drug therapy with captopril in children and adolescents. Clin Exp Hypertens A. 1986;8(4–5):829–39.PubMedCrossRef

17.

Sinaiko AR, Mirkin BL, Hendrick DA, Green TP, O'Dea RF. Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease. J Pediatr. 1983;103(5):799–805.PubMedCrossRef

18.

Tack ED, Perlman JM. Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr. 1988;112(5):805–10.PubMedCrossRef

19.

National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555–76.CrossRef

20.

Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. 2002;42(8):870–80.PubMedCrossRef

21.

Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens. 2003;16(10):795–800.PubMedCrossRef

22.

United States Food and Drug Administration. New pediatric labeling information database. http://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=labelingdatabase. Accessed 8 Jul 2014.

23.

Li JS, Berezny K, Kilaru R, Hazan L, Portman R, Hogg R, et al. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? Hypertension. 2004;44(3):289–93. doi:10.1161/01.HYP.0000138069.68413.f0.PubMedCrossRef

24.

Menon S, Berezny KY, Kilaru R, Benjamin Jr DK, Kay JD, Hazan L, et al. Racial differences are seen in blood pressure response to fosinopril in hypertensive children. Am Heart J. 2006;152(2):394–9. doi:10.1016/j.ahj.2005.12.025.PubMedCrossRef

25.

Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med. 2004;141(8):614–27.PubMedCrossRef

26.

United States Food and Drug Administration. Summaries of medical and clinical pharmacology reviews. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM161981.pdf. Accessed 8 Jul 2014.

27.

United States Food and Drug Adminsitration. Summaries of medical and clinical pharmacology reviews. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM163259.pdf. Accessed 8 Jul 2014.

28.

Shahinfar S, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens. 2005;18(2 Pt 1):183–90. doi:10.1016/j.amjhyper.2004.09.009.PubMedCrossRef

29.•

Webb NJ, Wells TG, Shahinfar S, Massaad R, Dankner WM, Lam C, et al. A randomized, open-label, dose-response study of losartan in hypertensive children. Clin J Am Soc Nephrol. 2014. doi:10.2215/CJN.11111113. Study showed that losartan is effective in lowering the blood pressure in children aged 6 months to 6 years, though no dose–response relationship was observed.PubMed

30.

Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich). 2008;10(10):743–50. doi:10.1111/j.1751-7176.2008.00022.x.CrossRef

31.

Schaefer F, van de Walle J, Zurowska A, Gimpel C, van Hoeck K, Drozdz D, et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens. 2010;28(5):1083–90. doi:10.1097/HJH.0b013e328336b86b.PubMedCrossRef

32.

Tullus K. Safety concerns of angiotensin II receptor blockers in preschool children. Arch Dis Child. 2011;96(9):881–2. doi:10.1136/archdischild-2011-300172.PubMedCrossRef

33.•

Hazan L, Hernandez Rodriguez OA, Bhorat AE, Miyazaki K, Tao B, Heyrman R. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension. 2010;55(6):1323–30. doi:10.1161/HYPERTENSIONAHA.109.147702. One of the few pediatric trials to compare the efficacy of angiotensin blockade in black and predominantly non-black patient cohorts.PubMedCrossRef

34.

Sakarcan A, Tenney F, Wilson JT, Stewart JJ, Adcock KG, Wells TG, et al. The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol. 2001;41(7):742–9.PubMedCrossRef

35.

Franscini LM, Von Vigier RO, Pfister R, Casaulta-Aebischer C, Fossali E, Bianchetti MG. Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. Am J Hypertens. 2002;15(12):1057–63.PubMedCrossRef

36.

37.

Trachtman H, Frank R, Mahan JD, Portman R, Restaino I, Matoo TK, et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol. 2003;18(6):548–53. doi:10.1007/s00467-003-1134-0.PubMed

38.

Tallian KB, Nahata MC, Turman MA, Mahan JD, Hayes JR, Mentser MI. Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol. 1999;13(4):304–10.PubMedCrossRef

39.

Flynn JT, Smoyer WE, Bunchman TE. Treatment of hypertensive children with amlodipine. Am J Hypertens. 2000;13(10):1061–6.PubMedCrossRef

40.

Rogan JW, Lyszkiewicz DA, Blowey D, Khattak S, Arbus GS, Koren G. A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatr Nephrol. 2000;14(12):1083–7.PubMedCrossRef

41.

von Vigier RO, Franscini LM, Bianda ND, Pfister R, Casaulta Aebischer C, Bianchetti MG. Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. J Hum Hypertens. 2001;15(6):387–91. doi:10.1038/sj.jhh.1001203.CrossRef

42.

Andersen J, Groshong T, Tobias JD. Preliminary experience with amlodipine in the pediatric population. Am J Ther. 2006;13(3):198–204. doi:10.1097/01.mjt.0000147593.73888.d5.PubMedCrossRef

43.

Flynn JT. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. Pediatr Nephrol. 2005;20(5):631–5. doi:10.1007/s00467-004-1781-9.PubMedCrossRef

44.

Flynn JT, Nahata MC, Mahan Jr JD, Portman RJ. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. J Clin Pharmacol. 2006;46(8):905–16. doi:10.1177/0091270006289844.PubMedCrossRef

45.

Flynn JT, Newburger JW, Daniels SR, Sanders SP, Portman RJ, Hogg RJ, et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr. 2004;145(3):353–9. doi:10.1016/j.jpeds.2004.04.009.PubMedCrossRef

46.

Lyszkiewicz DA, Levichek Z, Kozer E, Yagev Y, Moretti M, Hard M, et al. Bioavailability of a pediatric amlodipine suspension. Pediatr Nephrol. 2003;18(7):675–8. doi:10.1007/s00467-003-1088-2.PubMed

47.

Nahata MC, Morosco RS, Hipple TF. Stability of amlodipine besylate in two liquid dosage forms. J Am Pharm Assoc (Wash). 1999;39(3):375–7.

48.

Batisky DL, Sorof JM, Sugg J, Llewellyn M, Klibaner M, Hainer JW, et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr. 2007;150(2):134–9, 139.e1. doi:10.1016/j.jpeds.2006.09.034.

49.

Sorof JM, Cargo P, Graepel J, Humphrey D, King E, Rolf C, et al. Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol. 2002;17(5):345–50. doi:10.1007/s00467-002-0851-0.PubMedCrossRef

50.

Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47(3):312–8. doi:10.1161/01.HYP.0000201443.63240.a7.PubMedCrossRef

51.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17. doi:10.1056/NEJM199909023411001.PubMedCrossRef

52.

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21. doi:10.1056/NEJMoa030207.PubMedCrossRef

53.

Loggie JM. Hypertension in children and adolescents. II. Drug therapy. J Pediatr. 1969;74(4):640–54.PubMedCrossRef

54.

Li JS, Flynn JT, Portman R, Davis I, Ogawa M, Shi H, et al. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. J Pediatr. 2010;157(2):282–7. doi:10.1016/j.jpeds.2010.02.042.PubMedCrossRef

55.

Sullivan JE, Keefe D, Zhou Y, Satlin L, Fang H, Yan JH. Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension. Clin Pediatr (Phila). 2013;52(7):599–607. doi:10.1177/0009922813483875.CrossRef

56.•

Welch WP, Yang W, Taylor-Zapata P, Flynn JT. Antihypertensive drug use by children: are the drugs labeled and indicated? J Clin Hypertens (Greenwich). 2012;14(6):388–95. doi:10.1111/j.1751-7176.2012.00656.x. Investigated the drugs prescribed to hypertensive children to determine to what extent antihypertensive medications used in children have FDA-approved pediatric labeling.CrossRef

57.

Chaturvedi S, Lipszyc DH, Licht C, Craig JC, Parekh R. Pharmacological interventions for hypertension in children. Cochrane Database Syst Rev. 2014;2, CD008117. doi:10.1002/14651858.CD008117.pub2.PubMed

Title: Treatment of Pediatric Hypertension: Lessons Learned from Recent Clinical Trials
Authors: Michael A. Ferguson
Joseph T. Flynn
Publication date: 01-09-2014
Publisher: Springer US
Published in: Current Cardiovascular Risk Reports / Issue 9/2014
Print ISSN: 1932-9520
Electronic ISSN: 1932-9563
DOI: https://doi.org/10.1007/s12170-014-0399-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Treatment of Pediatric Hypertension: Lessons Learned from Recent Clinical Trials

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content